Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Montelukast Sodium
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
IntelGenx Reports Preliminary Results for Montelukast VersaFilm® in Alzheimer’s Disease
Details : Montelukast VersaFilm (montelukast) is a small molecule CysLT1 receptor inhibitor, given in the form of buccal film, is currently being ivestigated for patients with alzheimer's disease.
Product Name : Montelukast VersaFilm
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 03, 2024
Lead Product(s) : Montelukast Sodium
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Montelukast Sodium
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
IntelGenx Doses First Parkinson’s Patients with Montelukast VersaFilm in Phase 2 Trial
Details : Montelukast VersaFilm (montelukast) is a leukotriene receptor antagonist, which is being evaluated in patients with Parkinson’s Disease, the second most common neurodegenerative disease.
Product Name : Montelukast VersaFilm
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 08, 2024
Lead Product(s) : Montelukast Sodium
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Montelukast Sodium
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VersaFilm® (montelukast) is a leukotriene receptor antagonist, which is completed patient enrollment in the ongoing Phase 2a clinical trial in patients with mild to moderate Alzheimer’s Disease.
Product Name : Montelukast VersaFilm
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 14, 2023
Lead Product(s) : Montelukast Sodium
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Montelukast Sodium
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : VersaFilm® (montelukast) is a leukotriene receptor antagonist, which is completed patient enrollment in the ongoing Phase 2a clinical trial in patients with mild to moderate Alzheimer’s Disease.
Product Name : Montelukast VersaFilm
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 01, 2023
Lead Product(s) : Montelukast Sodium
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Montelukast Sodium
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Karolinska University Hospital
Deal Size : $2.0 million
Deal Type : Agreement
Details : The agreement aims to investigate the use of IntelGenx’s Montelukast VersaFilm, a leukotriene receptor antagonist, for the treatment of Parkinson’s Disease.
Product Name : Montelukast VersaFilm
Product Type : Miscellaneous
Upfront Cash : Undisclosed
July 25, 2023
Lead Product(s) : Montelukast Sodium
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Karolinska University Hospital
Deal Size : $2.0 million
Deal Type : Agreement
Lead Product(s) : Montelukast Sodium
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Karolinska Institute
Deal Size : $2.0 million
Deal Type : Collaboration
Details : Upon completion of the Study, IntelGenx will retain the intellectual property rights and use the findings to further develop its Montelukast VersaFilm® program for Parkinson's disease treatment.
Product Name : Montelukast VersaFilm
Product Type : Miscellaneous
Upfront Cash : Undisclosed
February 09, 2023
Lead Product(s) : Montelukast Sodium
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Karolinska Institute
Deal Size : $2.0 million
Deal Type : Collaboration
Lead Product(s) : Montelukast Sodium
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Montelukast Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 08, 2022
Lead Product(s) : Montelukast Sodium
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Montelukast Sodium
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Montelukast Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 06, 2022
Lead Product(s) : Montelukast Sodium
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Montelukast Sodium
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Resumption of patient dosing in the ongoing Phase 2a (BUENA) clinical trial of Montelukast VersaFilm, a leukotriene receptor antagonist on the basis of Phase 1 study data that reduces the first-pass-effect and has a 52% higher bioavailability.
Product Name : Montelukast VersaFilm
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 20, 2022
Lead Product(s) : Montelukast Sodium
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Montelukast Sodium
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In Phase 1 studies, an oral film formulation of Montelukast is safe and tolerable in healthy subjects, reduces the first-pass-effect and has a 52% higher bioavailability compared to the Montelukast tablet, demonstrating a clear advantage of delivering Mo...
Product Name : Montelukast VersaFilm
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 12, 2021
Lead Product(s) : Montelukast Sodium
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable